LYEL

Over the past six months (April 2026 - October 2026), Lyell Immunopharma's stock (LYEL) experienced a significant decline of -63.71%, with its 52-week high at $45.00 and low at $8.21. As of October 5, 2026, the stock price was $9.070, down 70.53% year-to-date. In May 2026, the company reported Q1 2026 financial results and business highlights, including updates on the PiNACLE pivotal clinical trial, commencement of patient dosing in the PiNACLE-H2H Phase 3 trial, continued enrollment in the LYL273 Phase 1 clinical trial, and the closing of a $50 million private placement tranche. In March 2026, Needham initiated coverage with a 'Buy' recommendation, and Citizens initiated coverage with a 'Market Outperform' recommendation. In the past month (September-October 2026), one analyst upgraded the stock, with no downgrades, and the average rating from six firms is 'Moderate Buy,' despite some 'sell' recommendations. The stock has been in a prolonged decline since its 2021 IPO, reflecting a lack of major clinical or regulatory milestones and consistent net losses.